Endo, Inc. (NDOI)
| Market Cap | 1.80B |
| Revenue (ttm) | 1.73B |
| Net Income (ttm) | 5.67B |
| Shares Out | 76.31M |
| EPS (ttm) | 65.93 |
| PE Ratio | 0.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Average Volume | 96,674 |
| Open | 23.54 |
| Previous Close | 23.10 |
| Day's Range | 23.50 - 23.59 |
| 52-Week Range | 19.85 - 31.40 |
| Beta | n/a |
| RSI | 67.33 |
| Earnings Date | Aug 6, 2025 |
About bluebird bio
Endo, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It is involved in the developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The company offer... [Read more]
Full Company ProfileNews
Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
MALVERN, Pa. , July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during t...
Endo to Report Second Quarter 2025 Financial Results on August 6, 2025
MALVERN, Pa. , July 21, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will report second quarter 2025 financial results on August 6, 2025, prior to ma...
Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.
Closing of the Merger Expected in Early August DUBLIN , July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given the necessary ruling to enable its combinati...
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #biotech--Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat primary adrenal insuffi...
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
PRESS RELEASE OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH e...
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
Endo Completes International Pharmaceuticals Business Divestiture
MALVERN, Pa. , June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmace...
Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Mallinckrodt to Apply to Irish High Court for Approval of Scheme of Arrangement DUBLIN and MALVERN, Pa. , June 13, 2025 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) (...
Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses Generics & Sterile Injectables Spin-Off to be Called Pa...
Endo Champions Men's Health Month with Education, Awareness, and Outreach
MALVERN, Pa. , June 2, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health and addressing health issue...
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...
Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
Endo's products are the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag MALVERN, Pa. , May 15, 2025 /PRNewswire/ -- End...
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
S-4 Registration Statement Effective; HSR Waiting Period Expired Irish High Court Approves Convening of Shareholder Meetings Shareholder Vote Scheduled for June 13 DUBLIN and MALVERN, Pa. , May 13, 20...
Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
XIAFLEX® revenues grew 7% compared to first-quarter 2024 The Company reaffirms 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million Combination with M...
Endo's New Spatial Computing Injection Simulator for Peyronie's Disease Creates Immersive Learning Environment for Urology Specialists
Endo Will Launch the Simulator at the American Urological Association (AUA) Annual Meeting MALVERN, Pa. , April 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of a Spatia...
Endo to Report First Quarter 2025 Financial Results on May 7, 2025
MALVERN, Pa. , April 7, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will report first quarter 2025 financial results on May 7, 2025, prior to market...
Endo Launches Spatial Computing Simulator to Create a Fully Immersive Learning Environment for Hand Specialists
- Endo is the first pharmaceutical company to launch an external spatial computing program.- The Spatial Computing Injection Simulator allows hand specialists to interact simultaneously with both phys...
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
MALVERN, Pa. , March 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of recu...
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of End...
Endo International plc (ENDPQ) Q4 2024 Earnings Call Transcript
Endo International plc (OTC:ENDPQ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Laure Park - Senior Vice President of Investor Relations and Corporate Affairs of End...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Endo, Inc.
NEW YORK , March 13, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Endo, Inc. (OTCQX: NDOI) and its board of directors concerning the proposed acquisitio...
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Endo, Inc. - NDOI
NEW YORK , March 13, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 IS...
NDOI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Endo, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Endo, Inc. (OTCQX: NDOI) and Mallinckrodt plc is fair to Endo shareholders. Under the t...
Shareholder Alert: The Ademi Firm Investigates Whether Endo, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Endo (OTCQX: NDOI) for possible breaches of fiduciary duty and other violations of law in its transaction with Mallinckrodt. Click here to l...